Firms will work on a chimeric factor VIII protein and a cell therapy.

Lentigen and Expression Therapeutics are collaborating to develop novel cell and protein therapies for hemophilia A. Expression Therapeutics high-expression factor VIII technology will be combined with Lentigen’s protein expression and gene transfer capabilities.


The companies will develop two types of treatments: a chimeric factor VIII protein for direct injection and a cell therapy that may permanently correct the disorder. “Factor VIII is a difficult protein to manufacture, but Lentigen’s protein expression technology will permit the production of a novel human factor VIII protein at levels highly favorable for commercialization,” notes Boro Dropulic, president and CSO of Lentigen. 


“Secondly, Expression Therapeutics’ proprietary factor VIII will be used in a novel stem cell therapy for hemophilia A that aims to restore the clotting capability of patients suffering from this debilitating disease.”



 

Previous articleScientists Disprove Proposed Theory of Nervous System Development
Next articleThe Genome Center at Washington University Adds 21 Illumina Sequencers